| Idecabtagene vicleucel for relapsed/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium DK Hansen, S Sidana, LC Peres, C Colin Leitzinger, L Shune, ... Journal of Clinical Oncology 41 (11), 2087-2097, 2023 | 133 | 2023 |
| Central nervous system relapse in adults with acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation A Hamdi, R Mawad, R Bassett, A di Stasi, R Ferro, A Afrough, R Ram, ... Biology of Blood and Marrow Transplantation 20 (11), 1767-1771, 2014 | 56 | 2014 |
| Symptomatic BK virus infection is associated with kidney function decline and poor overall survival in allogeneic hematopoietic stem cell recipients A Abudayyeh, A Hamdi, H Lin, M Abdelrahim, G Rondon, BS Andersson, ... American Journal of Transplantation 16 (5), 1492-1502, 2016 | 49 | 2016 |
| Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy CJ Ferreri, MAT Hildebrandt, H Hashmi, LO Shune, JP McGuirk, ... Blood cancer journal 13 (1), 117, 2023 | 36 | 2023 |
| Impact of induction therapy on the outcome of immunoglobulin light chain amyloidosis after autologous hematopoietic stem cell transplantation A Afrough, RM Saliba, A Hamdi, M Honhar, A Varma, AM Cornelison, ... Biology of Blood and Marrow Transplantation 24 (11), 2197-2203, 2018 | 29 | 2018 |
| HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant A Ghobadi, DR Milton, L Gowda, G Rondon, RF Chemaly, A Hamdi, ... Current research in translational medicine 67 (2), 51-55, 2019 | 23 | 2019 |
| Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis BK Ragon, MV Shah, A D’Souza, N Estrada-Merly, L Gowda, G George, ... Blood advances 7 (12), 2746-2757, 2023 | 20 | 2023 |
| Impact of hepatitis B core antibody seropositivity on the outcome of autologous hematopoietic stem cell transplantation for multiple myeloma A Varma, L Biritxinaga, RM Saliba, M Stich, SF Jauch, A Afrough, ... Biology of Blood and Marrow Transplantation 23 (4), 581-587, 2017 | 20 | 2017 |
| Poor immune reconstitution is associated with symptomatic BK polyomavirus viruria in allogeneic stem cell transplant recipients A Abudayyeh, A Hamdi, M Abdelrahim, H Lin, VD Page, G Rondon, ... Transplant Infectious Disease 19 (1), e12632, 2017 | 19 | 2017 |
| Idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory multiple myeloma (RRMM) who have received a prior BCMA … CJ Ferreri, MAT Hildebrandt, H Hashmi, LO Shune, JP McGuirk, ... Blood 140 (Supplement 1), 1856-1858, 2022 | 15 | 2022 |
| Idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma (RRMM): Real-world experience. DK Hansen, S Sidana, L Peres, L Shune, DW Sborov, H Hashmi, ... Journal of Clinical Oncology 40 (16_suppl), 8042-8042, 2022 | 15 | 2022 |
| On-versus off-pump coronary artery bypass grafting: No difference in early postoperative kidney function based on TNF-α or C-reactive protein N Nezami, H Djavadzadegan, H Tabatabaie-Adl, A Hamdi, K Ghobadi, ... Cardiorenal medicine 2 (3), 190-199, 2012 | 13 | 2012 |
| Safety and efficacy of teclistamab in patients with relapsed/refractory multiple myeloma: a real-world experience D Dima, JA Davis, N Ahmed, X Jia, A Sannareddy, H Shaikh, L Shune, ... Transplantation and cellular therapy 30 (3), 308. e1-308. e13, 2024 | 11 | 2024 |
| Real world outcomes with idecabtagene vicleucel (ide-cel) CAR-T cell therapy for relapsed/refractory multiple myeloma S Sidana, N Ahmed, OS Akhtar, M Heim, R Brazauskas, DK Hansen, ... Blood 142, 1027, 2023 | 11 | 2023 |
| Racial and ethnic differences in clinical outcomes among multiple myeloma patients treated with CAR T therapy LC Peres, LB Oswald, C Dillard, G De Avila, T Nishihori, BJ Blue, ... Blood 140 (Supplement 1), 623-625, 2022 | 11 | 2022 |
| Cell Therapy AP Gee Springer, 2009 | 11 | 2009 |
| Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment S Sidana, LC Peres, H Hashmi, H Hosoya, C Ferreri, J Khouri, D Dima, ... Haematologica 109 (3), 777, 2024 | 9 | 2024 |
| Idecabtagene vicleucel chimeric antigen receptor T-Cell therapy for relapsed/refractory multiple myeloma with renal insufficiency: real world experience S Sidana, LC Peres, H Hashmi, H Hosoya, CJ Ferreri, S Atrash, J Khouri, ... Blood 140 (Supplement 1), 10377-10379, 2022 | 9 | 2022 |
| Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation A Varma, RM Saliba, HA Torres, A Afrough, C Hosing, IF Khouri, Y Nieto, ... Bone marrow transplantation 51 (7), 999-1001, 2016 | 8 | 2016 |
| Outcome of patients with immunoglobulin light-chain amyloidosis with lung, liver, gastrointestinal, neurologic, and soft tissue involvement after autologous hematopoietic stem … A Afrough, RM Saliba, A Hamdi, R El Fakih, A Varma, YT Dinh, G Rondon, ... Biology of Blood and Marrow Transplantation 21 (8), 1413-1417, 2015 | 8 | 2015 |
